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Figure 3:  Doxorubicin treatment results in body-mass atrophy,  adding creatine 
results in additional liver atrophy
(Left) Liver to bodyweight ratio. Line drawn at 3.0% is “normal” ratio.
• Liver-Bodyweight ratio elevated with doxorubicin treatment. Significant difference between 
DOX/SAL & 2% CRE/DOX (P-value: 0.00071). Bodyweight decreased with doxorubicin treatment 
while liver weight remained normal. Bodyweight and liver weight decrease with creatine 
treatment. 
(Right) qPCR indicate elevated mRNA expression of BAX (apoptotic marker)  all CRE/DOX treatments.
Figure 1: Serum chemistry and H&E stain indicate signs of hepatotoxicity in doxorubicin and 2% creatine/doxorubicin 
group. Serum ALT/AST ratio attenuated in 4/2% creatine/doxorubicin.
Question and Methods: 
Experimental Question: Does creatine supplementation alleviate doxorubicin induced hepatotoxicity and if so, 
what dose works best?
• Sprague-Dawley rats (Rattus norvegicus) were used as a model organism
• Six treatment groups consisting of four rats each received either saline (CTR), 2% creatine/saline (2%CRESAL), 
4X2%creatine/saline (4/2CRESAL), doxorubicin (DOX), 2%creatine/doxorubicin (2%CREDOX), 4X2% creatine/doxorubicin 
(4/2CREDOX). 
• Creatine supplementation lasted for 2 weeks, followed by an injection of doxorubicin.
• The treatment groups were anesthetized and sacrificed after treatment. Liver samples and serum were then collected. Tissue 
was snap frozen with liquid nitrogen. 
• Liver function was examined by serum chemistry. 
• Liver to bodyweight ratio was calculated. 
• H&E staining, Senescence staining and Sirius red staining were used to examine the liver damage and liver fibrosis 
histologically.
• Genomic DNA and total RNA was also isolated and used to examine global methylation and apoptotic, senescent and 
fibrotic biomarkers through ELISA and qPCR. 
Figure 2: Creatine supplementation reverses doxorubicin induced global 
methylation reduction and senescence.
(Top) Immunohistochemistry stain for 
senescent biomarker. Presence of (MCP-1) 
biomarker for senescence is stained black.
Senescent cells within the liver prevent 
regeneration and are active in a secretory 
manner.[6]
• Doxorubicin treatment initiates 
noticeable senescence that is 
mediated by the creatine treatment; 
2%CREDOX shows a reduction in 
biomarker, while 4/2% CRE/DOX 
shows no sign of senescence.
(Middle) qPCR results indicate relative 
expression of p16 and MCP-1 mRNA 
(senescent biomarkers).
• Results appear to correlate with 
tissue staining above. 
(Bottom) 5-mC%. DNA isolated from 
treatment groups ran against a sandwich 
ELISA that specifically targets 5-
methylCytosine. Reduction in 5-
methylCytosine is indicative of DNA damage. 
• Doxorubicin treatment significantly 
reduces 5-mC% (P<.01) compared to 
control. Creatine appears to increase 
methylation patterns in all treatment 
groups. 
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(Top) Sirius red staining. Nucleus appear dark. Lipids stained yellow and collagen fibers selectively stained 
red. Red pixels quantified using imaging software. Significant difference (P<.05) between DOX treatment 
group and 2%CRE/DOX group.
(Bottom) qPCR results indicate relative expression of Col1A1 (marker for fibrosis) and CK-19 (marker for 
biliary damage). Results show elevated markers in 2%CRE/DOX group but not 4/2%CRE/DOX
Figure 4: Creatine/Doxorubicin treatment induces fibrosis in a 
dose dependent manner.
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(Top) Sirius red staining. Nucleus appear dark. Lipids stained yellow and collagen 
fibers selectively stained red. Sirius red selectively shows fibrosis. Red pixels 
quantif ed usi g imaging software.
• Significant difference (P<.05) between DOX treatment group and 2%CRE/DOX 
group.
(Bottom) qPCR results indicate relative expression of Col1A1 (marker for fibrosis) and 
CK-19 (marker for biliary damage).
• Results show elevated markers in 2%CRE/DOX group.
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(Top)  Serum chemistry analysis of 
CREDOX sample groups using 
lipids(lipemia), liver metabolites(t-
bilirubin), and liver enzymes 
(ALP,ALT/AST ratio, ALT,AST). 
Clinical significance is indicated 
by the AST/ALT ratio.[5]
• Bilirubin elevated in doxorubicin 
treatments(DOX,2%CRE/DOX,4/2
%CRE/DOX).
• Significantly elevated AST/ALT 
ratio (P<.05) and elevated AST in 
DOX and 2%CRE/DOX indicate 
liver toxicity.
• Significant difference between 
2%CRE/SAL and 4/2%CRE/DOX 
(P<.05) and between 
4/2%CRE/SAL and 4/2%CREDOX 
(P<.05) for ALP.
(Bottom) H&E staining of hepatic 
portal vein, artery, and biliary duct. 
Nucleus stained dark purple, acidic 
proteins in cytoplasm stained pink.
• Noticeably thicker vascular walls 
and more nuclei in control 
groups compared to doxorubicin 
treatment. 
• Pink eosin staining appears more 
intense in doxorubicin groups 
which indicates protein 
accumulation or lower ph. Signs
of cell stress.
• 4/2% CRE/DOX sample tissue 
dried and difficult to distinguish. 
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Background: 
• Doxorubicin AKA “the red devil” is a chemotherapeutic drug used to treat a wide range of cancers.[1]
• Doxorubicin’s mechanism of inducing toxicity is multifaceted in this regard. The overall result being cell death. 
• It is believed to a.) induce mitochondrial stress leading to an increase of reactive oxygen species and b.) inhibit 
the activity of DNA repair mechanisms. [1]
• While advantageous when fighting doxorubicin toxicity presents a serious risk to a patients own tissues. Severe cases 
of cardiotoxicity are often associated with treatment, manifesting within weeks or years of treatment.[2]
• Liver failure is another rare but serious side effect.[3] 
• Routes of mitigating these deleterious symptoms is an ongoing area of research. Creatine is a proposed 
intervention due to its ergogenic and safe use. 
• Creatine can increase intracellular ATP availability in numerous tissues.[4] Creatine has been shown to successfully 
reduce the dystrophic effects on skeletal muscle and reduce cardio myocellular injury.[4]
Conclusion: Creatine alleviates doxorubicin toxicity in a dose 
dependent manner. Higher doses (4X2% creatine) appear to 
mediate and reverse the signs of hepatotoxicity. Lower doses 
(2%creatine) interact negatively and show signs of amplifying 
hepatotoxicity.
1. Significant changes in serum chemistry indicates liver toxicity 
in doxorubicin and 2%Creatine/Doxorubicin treatments which 
is alleviated in the 4X2% Creatine/Doxorubicin treatment. 
(Figure 1)
i. Intense eosin in H&E staining shows protein accumulation 
in doxorubicin treatments and degrading vascular wall in 
2%Creatine/Doxorubicin treatment.(Figure 1)
2. Senescence induced by doxorubicin is reversed by creatine 
treatment. (Figure 2)
i. Magnitude appears to be affected by dose. (Figure 2)
3. Global hypomethylation is improved with creatine treatment. 
(Figure 2)
4. Creatine causes higher levels of liver atrophy and fibrosis in 
the 2%Creatine treatment compared to the 4X2% Creatine 
treatments. (Figure 3 & 4)
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